| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/JAM.2006.19.456 |
| P698 | PubMed publication ID | 17196074 |
| P2093 | author name string | Overbeek SE | |
| Standaert TA | |||
| Tiddens HA | |||
| Speirs RJ | |||
| Humble D | |||
| Geller DE | |||
| Shrewsbury SB | |||
| Challoner P | |||
| Kesser KC | |||
| P433 | issue | 4 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| patient | Q181600 | ||
| P304 | page(s) | 456-465 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Journal of Aerosol Medicine and Pulmonary Drug Delivery | Q15752401 |
| P1476 | title | Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. | |
| P478 | volume | 19 |
| Q36200226 | Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design |
| Q50736432 | Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children. |
| Q58275438 | Development of Variable Flow Rate Isokinetic Sampling System for 0.5–15-μm Aerodynamic Diameter Particles |
| Q37851986 | Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology |
| Q38474246 | Devices for dry powder drug delivery to the lung |
| Q39143592 | Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication |
| Q27324278 | Effect of inhaler design variables on paediatric use of dry powder inhalers |
| Q38126940 | Improved laboratory test methods for orally inhaled products |
| Q38364686 | Inhalation drug delivery devices: technology update |
| Q41071899 | Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study |
| Q40505534 | Inhalation of tobramycin using simulated cystic fibrosis patient profiles |
| Q46275410 | Inhaled therapies in cystic fibrosis |
| Q41975905 | Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device |
| Q37601392 | Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device |
| Q37804379 | New Antimicrobial Strategies in Cystic Fibrosis |
| Q38645125 | Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models |
| Q41362700 | Prerequisites for a dry powder inhaler for children with cystic fibrosis |
| Q33861117 | Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial |
| Q83156270 | Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis |
| Q90715578 | The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates |
| Q40525155 | The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler |
| Q38980035 | The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers |
| Q26829604 | Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q38037076 | Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review. |
| Q39282311 | Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence |
| Q38160206 | Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q38358856 | Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis |
Search more.